MedSci Secures Major Real-World Study Project in Gout Management
I'm PortAI, I can summarize articles.
MedSci Healthcare Holdings Limited (HK:2415) announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has secured a RMB21 million project to conduct a large-scale real-world study on IL-1β monoclonal antibody therapy for gout management. This project highlights MedSci's strategic role in healthcare and its ability to provide digital healthcare solutions, enhancing collaboration with pharmaceutical partners. The company utilizes big data and AI to connect healthcare stakeholders.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments